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Implication for health policy/practice/research/medical education:
This article presents that Eprex as an analogue of  erythropoietin is a promising renoprotective drug to pre-
vent or attenuate tubular damage induced by gentamicin.
Please cite this paper as:  Raﬁeian-Kopaei M, Nasri H, Nematbakhsh M, Baradaran A, Gheissari A, Rouhi H, 
Ahmadi Soleimani SM, Baradaran-Ghahfarokhi M, Ghaed-Amini F, Ardalan MR.Erythropoietin ameliorates 
gentamycin-induced renal toxicity: A biochemical and histopathological study.
J Nephropathology. 2012; 1(2): 109-116, DOI:10.5812/nephropathol.7533 
*Corresponding author: Prof. Mahmoud Raﬁeian-Kopaei, Medical Plants Research Center, Shahrekord University of  Medical 
Sciences, Shahrekord, Iran. Telephone: 00983813346692, Fax: 00983813330709, Email: raﬁeian@yahoo.com
1  Medical Plants Research  Center, Shahrekord University of  Medical Sciences, Shahrekord, Iran.
2 Department  of  Nephrology, Division of  Nephropathology, Isfahan University of  Medical Sciences, Isfahan, Iran
3  Water and   Electrolytes Research  Center, Department of  Physiology, Isfahan University of  Medical Sciences, Isfahan, Iran.
4 Department of  Clinical Pathology, Isfahan University of  Medical Sciences, Isfahan , Iran. 
5 Isfahan Kidney Disease Research Center, Isfahan University of  Medical Sciences, Isfahan , Iran.
6 Department of  Physiology, Faculty of  Medical Sciences, Tarbiat Modares University, Tehran, Iran.
7 Medical Physics and Medical Engineering Department, Isfahan University of  Medical Sciences, Isfahan, Iran.
8 Department of  Nephrology, Tabriz University of  Medical Sciences, Tabriz, Iran. 
www.nephropathol.com                    DOI: 10.5812/nephropathol.7533                     J Nephropathology. 2012; 1(2): 109-116
Journal of  Nephropathology
See commentaries on pages 81 and 83
ARTICLE INFO
Article type:
Original Article
Article history:
Received: 07 Dec 2011
Revised: 15 Dec 2011
Accepted: 03 Jan 2012
Published online: 1 July 2012
DOI: 10.5812/nephropathol.7533
Keywords:
Gentamicin
Tubular toxicity
Erythropoietin
ABSTRACT
Background: Investigations have attempted to modify the outcome of  tubular in-
jury by either ameliorating renal tubular damage or promoting tubular regenera-
tion in the case of  acute tubular necrosis.
Objectives: We investigated the protective effect of  Eprex an erythropoietin ana-
logue on tubular injury   induced by gentamicin (GM).
Materials and Methods: Forty male Wistar rats were randomly divided into four 
groups. In group 1,rats were served as a sham group. In group 2, rats were in-
jected intraperitoneally with 100 mg/kg of  GM for 10 consecutive days (positive 
control group) and then were sacriﬁced. In group 3, rats received GM for 10 days 
then Eprex 100U/kg was injected intraperitoneally for the next 10 days and then 
they were sacriﬁced at the day 20th. In group 4 rats were injected a combination 
of  GM (80 mg/kg) and Eprex 100U/kg  intraperitoneally for 10 days and then 
were sacriﬁced.
Results: The results indicated that, Eprex prevented the increase in serum creati-
nine (Cr) and blood urea nitrogen (BUN). The effect of  Eprex on damage score, 
showed that co-administration of  GM and Eprex (group 3 and 4) reduced the 
kidney tissue damage compared to positive control group (P<0.05). This result 
indicat that Eprex potentially can reduce or prevent the kidney tissue damage. 
Conclusions: Ameliorative effect of  Eprex when the drug was given in combina-
tion with GM and also when the drug was applied after GM–induced tubular 
damage, revealed the renoprotective potency of  Eprex. Eprex is a promising 
drug to prevent or attenuate tubular damage induced by GM or other nephro-
toxic agents which act through the same mechanisms as gentamicin.
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1. Background
cute renal failure (ARF) is characterized 
by a rapid decline in glomerular ﬁltration 
rate over hours to several days, and the re-
tention of  nitrogenous waste products (1, 2). The 
mortality rate of  patients with ARF is remained 
25-70%, despite the use of  various pharmaco-
logic agents (2-5). Indeed, ARF frequently oc-
curs in critically ill patients and is an independent 
risk factor for poor outcome. The prevention of  
kidney injury in intensive care remains a great 
challenge as speciﬁc nephroprotective therapies 
are still lacking (6-8). Investigations have been at-
tempted to modify the outcome of  this disease 
especially in patients suffering from tubular in-
jury by either ameliorating renal tubular damage 
or promoting tubular regeneration in the case of  
acute tubular necrosis. However, to date, none of  
these modalities has made any appreciable clinical 
trend on the high mortality and morbidity rates 
associated with this condition (9). Unfortunately, 
in the clinical setting, most cases of  ARF are not 
identiﬁed until sometime after the insult has al-
ready occurred. Thus, the clinical utility of  any 
therapeutic agent for ARF would be greatly en-
hanced if  delayed administration of  the drug still 
proved to be effective in renoprotection. Several 
growth factors have been identiﬁed to regulate 
regeneration and repair (9, 10). Erythropoietin 
was ﬁrst characterized as a hematopoietic factor, 
and it has been used clinically for the treatment 
of  anemia (10-12). Erythropoietin is a cytokine 
that is produced primarily in the kidneys by renal 
cortical ﬁbroblasts (10, 11), and which regulates 
the differentiation and proliferation of  erythroid 
progenitor cells. However, due to in-vitro human 
recombinant erythropoietin stimulates endothe-
lial cell proliferation (10-12) and angiogenesis 
(10, 13, 14), erythropoietin effects may not be 
limited to bone marrow cells. Moreover, it has 
been shown to exert pleiotropic properties, such 
as cytoprotection, anti-inﬂammation and anti-
apoptosis, in the central nervous, kidney and liver 
(12-15). Studies also suggested that erythropoi-
etin may act directly on damaged tubular cells and 
stimulates their regeneration (9, 15). It has been 
shown that erythropoietin receptors are found 
on renal tubular epithelial, mesangial and endo-
thelial cells. This effect may be through activation 
signaling pathways to prevent apoptosis and/
or stimulate reparative proliferation of  the in-
jured cells (9, 14, 15). Gentamicin (GM) is widely 
known to induce ARF as a result of  renal tubular 
epithelial cell injury by direct acute tubular necro-
sis which is primarily localized to the proximal 
tubule. Nephrotoxicity is manifested by increased 
concentrations of  plasma urea nitrogen, serum 
creatinine and various histological aspects of  re-
nal tissue (16-19). Mechanisms of  renal injury 
include binding to anionic phospholipids and al-
tering the function and structure of  cellular and 
intracellular membranes (17-20). Furthermore, 
ATP depletion from either mitochondrial dam-
age or direct inhibition of  mitochondrial oxida-
tive phosphorylation (17-21) and reactive oxygen 
species (ROS) production are other mechanism 
take part in nephrotoxicity(18-20). Most stud-
ies reported previously were designed to admin-
ister drugs before or at the same time of  renal 
insult (18-24). However, most therapeutic agents 
are usually administered after the expression of  
clinical diseases. Indeed, most cases of  acute re-
nal failures are not identiﬁed until the insult has 
already occurred. Hence, the clinical utility of  
any therapeutic agent for this disease would be 
greatly enhanced if  delayed administration of  the 
drug still proved to be renoprotective. Whether 
delayed treatment with erythropoietin exerts sim-
ilar beneﬁts in ischemic, or toxic renal injury is 
still unknown. 
2. Objectives
In this study we aimed ﬁrstly to investigate the 
possible protecting effect of  erythropoietin on 
A
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GM-induced renal toxicity in rats and secondly 
to examine whether post treatment of  erythro-
poietin for tubular cell regeneration would be still 
beneﬁcial.  
3. Materials and Methods
 Our study is a randomized controlled trial, ap-
proved by the ethical committee of  Shahrekord 
University of  Medical Sciences. 
3.1. Drugs
 Human recombinant erythropoietin [Eprex 
(Epoetin Alfa), Janssen Cilag Ltd, Switzerland] 
was provided as a 2,000 IU/mL solution. The 
GM and erythropoietin treatment protocols used 
in the present study have been reported previ-
ously (25, 26).
3.2. Animal preparation  
 Study samples including 40 male Wistar rats 
with a weight range of  200-250 g were purchased 
from Ahvaz Jundishapur University of  Medical 
Sciences, Ahvaz, Iran. All animals were similar-
ly handled in the animal house of  our research 
center, had free access to food and water. They 
were housed in a temperature and humidity con-
trolled environment (25 ± 3 ° C, 50-60%), with a 
12 hrs dark-light cycle (lights on at 7.00 AM) and 
allowed free access to pelleted diet and tap water. 
Their general health state and activity were moni-
tored closely during the experiment. The animal 
experimentation was conducted in accordance 
with the National Institute of  Health guide for 
the careful use of  laboratory animals (27). They 
were allocated randomly to 4 groups (10 rats in 
each) .The study groups were assigned the fol-
lowing regimens:
 Group 1: Rats in this group were served as a 
sham group. They were kept in the same condi-
tion as others without receiving drugs for 10 days 
and then were sacriﬁced.
Group 2: Rats in this group were injected intra-
peritoneally with 100 mg/kg of  GM for 10 con-
secutive days (positive control group) and then 
were sacriﬁced. 
 Group 3: Rats in this group were received 
GM (100mg/kg) for 10 days then Eprex 100U/
kg was injected intraperitoneally for the next 10 
days and then the rats were sacriﬁced at the day 
20th.
 Group 4: Rats in this group were injected 
intraperitoneally with a combination of  GM 
(100mg/kg) and Eprex 100U/kg intraperitone-
ally for 10 days and then were sacriﬁced. 
 On the day one (before experiment) and on 
the ﬁnal day (day of  sacriﬁcing) serum samples 
were obtained to measure urea nitrogen (BUN) 
and creatinine (Cr) for all the rats. Blood samples 
were obtained and then rats were sacriﬁced by in-
jecting ketamine (i.p.) and kidneys were removed 
immediately for histological examinations.
 
3.3. Determination of  blood urea nitrogen (BUN) and 
serum creatinine level
 BUN and serum creatinine (Cr) level was mea-
sured by colorimetric method using commercial 
kits by an auto analyzer.
3.4. Histopathological evaluations
 The animal kidneys were removed, then ﬁxed 
in formalin for 12 hours and processed for histo-
pathological study. Four 2-3 μm-thick parafﬁn sec-
tions were stained with hematoxylin and eosin for 
light microscope examination using conventional 
protocol (28). Histopathological studies were 
performed under a light microscope. Slides were 
coded and were examined by a Nephropathologist 
(HN) who was blinded to the treatment groups. 
All specimens were examined for six morphologic 
parameters including epithelial cell vacuolization, 
degeneration, tubular cell ﬂattening, hyaline cast, 
tubular dilatation and debris materials in tubular 
lumen on a semi-quantitative score from 1 to 5. 
The score of   zero was assigned to the normal tis-
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sue without damage (29,30).
3.5. Statistical Analysis
 Data were expressed as mean ± SEM. One 
way ANOVA was applied to compare the serum 
BUN and Cr levels between the groups. To com-
pare the pathological damage score between the 
groups, Mann-Whitney or Kruskal-Wallis was ap-
plied. P<0.05 were considered statistically signiﬁ-
cant.
4. Results
4.1. The effect of  Eprex on BUN and Cr levels:
 Compared to others groups, the results in-
dicated that GM increased the levels of  BUN 
and Cr signiﬁcantly (P<0.05). However, Eprex 
prevented this increment. No signiﬁcant differ-
ence in serum BUN and Cr levels was detected in 
GM plus Eprex treated rats when compared with 
sham group (table 1).  
4.2. The effect of  Eprex on damage score 
 GM induced kidney damage (p<0.05). Co-
administration of  GM and Eprex (group 3 and 
4) reduced the kidney tissue damage when com-
pared with positive control group (P<0.05). This 
result indicated that Eprex potentially can reduce 
or prevent the kidney tissue damage (Figure 1).
5. Discussion
 In this study we found that Eprex could at-
tenuate GM-induced tubular toxicity. Numerous 
studies have been attempted to modify the out-
come of  acute tubular injury by either ameliorat-
ing tubular injury or promoting tubular regenera-
tion (9, 10, 31). While erythropoietin receptors 
Table 1: Serum levels of BUN and Cr in 4 groups of experiment. 
Group BUN (mg/dl) Cr (mg/dl)
before after ∆ before after ∆
1 21.80±0.49 22.60±0.65 0.8±0.72 0.54±0.02 0.55±0.02 0.01±0.02
2 21.75±0.43 77.90±16.28* 56±16.23* 0.54±0.01 1.55±0.33* 1.01±0.33*
3 21.80±0.49 31.60±1.08 9.8±1.17 0.54±0.02 0.59±0.03 0.05±0.02
4 21.78±0.55 45.22±2.09 23.4±2.09 0.54±0.02 0.81±0.03 0.26±0.04
P value n.s <0.01 <0.001 n.s <0.01 <0.01
*: Signiﬁcant difference from other groups.
Group 1; sham, group 2: GM treated for 10 days (positive control), group 3: GM treated for 10 days following by 
Eprex treated for 10 days, group 4; GM plus Eprex treated for 10 days. 
Ns: non–signiﬁcant, ∆: concentration difference (after-before)
Figure 1: Kidney tissue damage score in 4 groups of experiments. Group 1: sham; group 2: gentamicin treated for 10 days (positive con-
trol); group 3: gentamicin treated for 10 days following Eprex treatment for 10 days, group 4; gentamicin plus Epex treated for 10 days.
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are expressed on renal tubular epithelial cells (15, 
31), it is possible that the systemic administration 
of  erythropoietin may also provide protection 
against acute renal damage (15, 31). Erythropoi-
etin has also been found to ameliorate toxic re-
nal injury caused by Cisplatin (31, 32). Similarly, 
its renoprotective effect in ischemia–reperfusion 
renal injury, as the most common cause of  ARF 
in the community was also reported (15, 31). It 
seems that erythropoietin is not solely a hormone 
charged with regulating the proliferation and dif-
ferentiation of  erythroid progenitor cells (33, 34). 
Its erythropoietic function is mediated by anti-
apoptotic pathways, mainly involving Akt and 
the Bcl-2 gene family in bone marrow. Thereby, 
it facilitates the maturation and differentiation of  
erythroid progenitor cells (10, 15). The   effect is 
a compensatory adaptation to renal tissue hypoxia 
by augmenting the oxygen-carrying capacity of  
the blood (31). Recently, erythropoietin has been 
reported to have several important biological ef-
fects in addition to the stimulation of  erythropoi-
esis (8-11). Dang et al. found that renal tubular 
cells possess erythropoietin receptor reduces high 
glucose-induced oxidative stress in renal tubular 
cells (35). They have also found that erythropoi-
etin inhibited high glucose-induced renal tubu-
lar cell apoptosis. In their study, this protective 
effect was dependent on the reduction of  Bax/
caspase-3 expression and elevation of  Bcl-2 ex-
pression. They suggested that erythropoietin can 
inhibit high glucose-induced renal tubular cell 
apoptosis by direct effect on anti-oxidative stress 
and that erythropoietin receptor may play a key 
role in this process (35). Erythropoietin is reduced 
kidney dysfunction by decreasing apoptosis.  Also, 
erythropoietin has been shown to reduce the ex-
pression of  pro-inﬂammatory mediators, TNF-al-
pha and IL-2, in renal injury and reverse the effect 
of  endotoxin on the antioxidant, renal superoxide 
dismutase. These anti-inﬂammatory properties of  
erythropoietin also suggested the involvement of  
the NF-kB pathway through its kidney protection 
(15). While, erythropoietin is an extremely po-
tent stimulator of  endothelial progenitor cells, its 
function is partly dependent on nitric oxide bio-
availability. Erythropoietin activates endothelial 
nitric oxide synthase, and this effect on the en-
dothelium may be critical for its renal protective 
effect. Erythropoietin limits acute kidney injury in 
part by stimulating vascular repair and by increas-
ing tubular cell proliferation (31, 36, 37). These 
ﬁndings suggested that erythropoietin may exert 
a protective effect via an interaction with the mi-
crovasculature, too (15, 31, 36, 37). The cytopro-
tective and mitogenic effects of  erythropoietin 
on proximal and distal tubular epithelial cells may 
explain the observation of  a modest reduction in 
tubular cast formation in erythropoietin -treated 
rats following renal injury. Decreased cell slough-
ing and cast formation may be due to reduction 
in intra-tubular obstruction and a subsequent 
amelioration of  renal functional impairment 
(31). Previous investigators have also shown that 
erythropoietin exerts signiﬁcant mitogenic and 
anti-apoptotic actions in non-renal and non-ery-
throid cells, including endothelial and gastric mu-
cosal cells and similarly in myoblasts and Leydig 
cells (31,37). To explain the mechanisms toward 
erythropoietin-related renal protection, several 
hypotheses have been described. Rjiba-Touati et 
al. found that the protective effect of  erythro-
poietin against Cisplatin-induced oxidative stress 
and nephrotoxicity in rat kidney may be mediated 
through decreased oxidative damage induced by 
Cisplatin. Recombinant human erythropoietin re-
duced malondialdehyde and protein carbonyl lev-
els and also prevented glutathione depletion and 
ameliorated the increased catalase activity induced 
by Cisplatin treatment (38). They also found that, 
recombinant human erythropoietin restored cre-
atinine and blood urea nitrogen levels increased 
by Cisplatin. They  concluded that recombinant 
human erythropoietin administration especially 
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in pretreatment condition protected rats against 
Cisplatin-induced renal oxidative stress and neph-
rotoxicity(39). In another study conducted by 
Rjiba-Touati et al. to ﬁnd the protective effect of  
erythropoietin against Cisplatin-induced apopto-
sis in rat kidney, a reduction of  apoptosis by up 
regulation of  antiapoptotic protein expressions, 
down regulation of  pro apoptotic protein levels, 
and reduction of  caspase-3 activity in male Wistar 
rats was seen (40). Hence it seems that the protec-
tive action of  Eprex on the kidney probably is not 
directly related to its hematopoietic effects (14). 
Furthermore, various beneﬁcial effects of  eryth-
ropoietin  in preventing aristolochic acid-induced 
apoptosis in the cultured cells were investigated 
by Wang et al. (41). To understand the efﬁcacy of  
pretreatment with erythropoietin in the attenua-
tion of  radio contrast-induced acute renal failure 
in rats, Goldfarb et al. have conducted a study on 
twenty-two male rats. It their work, rats were sub-
jected to saline (controls) or erythropoietin injec-
tions (3000 U/kg and 600 U/kg, 24 and 2 h before 
the induction of  radio contrast-induced nephrop-
athy, respectively. They found that erythropoietin 
pre-treatment prevents renal dysfunction in a rat 
model of  contrast-induced nephropathy (42). In 
our study post-treatment of  GM-induced renal 
toxicity in group 4 had the same efﬁcacy with rats 
in group 3, where there was a combination thera-
py of  GM and Eprex. Thus we could assume that 
erythropoietin treatment is still effective when re-
nal injuries happen. 
 Aminoglysosides-induced nephrotoxicity is 
typically characterized by tubular necrosis (43). 
It seems that free radicals may be involved (20). 
Since, erythropoietin induces erythrocytosis by 
suppressing erythroid progenitor cell apoptosis 
through the Janus-activated kinase/signal trans-
ducers and activators of  transcription pathway 
(20, 44) and apoptosis contributes to GM-induced 
nephrotoxicity, we could speculate that the atten-
uation of  GM-induced nephrotoxicity by Eprex 
treatment of  is mediated through it’s antiapoptot-
ic actions as well. In a randomized, placebo-con-
trolled, clinical trial of  preoperative erythropoi-
etin in 71 patients who were underwent elective 
coronary artery bypass graft surgery, renoprotec-
tive effects of  erythropoietin was reported (45). 
Erythropoietin was given at a dose of  300 U/kg 
IV immediately preoperatively and was associated 
with a reduction in the incidence of  acute kidney 
injury from 29% to 8% and was improved post-
operative renal function as indicated by a smaller 
increase in serum Cr and a smaller decline in es-
timated glomerular ﬁltration rate postoperatively. 
Moore et al. assessed the effect of  erythropoietin 
in ICU patients deemed at risk for acute kidney 
injury (15). Erythropoietin was given at 500 U/
kg IV when a high GGT × ALP product was de-
tected and repeated 24 hours later. The primary 
outcome of  this study was the increase in the av-
erage percentage of  creatinine from baseline to 
its peak over 7 days. In contrast to the previous 
study, in a trial conducted by Endre et al., they 
found no renoprotective effect of  erythropoietin 
(46). The reasons for these contradictory ﬁndings 
may be due to the differences in the design and 
the methods of  the investigation.
 
6. Conclusions
 This study showed the renoprotective effect of  
Eprex, when the drug is given in combination with 
GM. Moreover, the protective effect of  Eprex was 
observed when the drug was applied after GM–in-
duced tubular damage and was revealed that the 
drug was still effective after installation of  tissue 
damage. Eprex is a promising renoprotective drug 
to prevent or attenuate tubular damage induced 
by GM or other nephrotoxic agents which act 
through the same mechanisms as gentamicin.
Author’s contributions
 MRK and HN designed and performed the 
research. MN analyzed data and wrote some parts 
of  paper. AB, AG, HR, SMAS, MBG, FGA and 
 www.nephropathol.com      Journal of  Nephropathology, Vol 1, No 2,  July 2012
Erythropoietin ameliorates gentamicin- renal toxicity…
115
MRA provided extensive intellectual contribu-
tion and reviewed the manuscript. HN and MRK 
prepared the manuscript.
Conﬂict of  interest
 The author declared no competing interests.
Funding/Support
 This study was granted by the research deputy 
of  Shahrekord University of  Medical Sciences 
(grant #994).
Acknowledgments
 The authors wish to thank staffs of  Medical 
Plants Research Center of  Shahrekord University 
of  Medical Sciences.
References
1. Prokai A, Fekete A, Banki NF, Muller V, Ver A, Degrell 
P, et al. Renoprotective effect of  erythropoietin in rats sub-
jected to ischemia/reperfusion injury: gender differences. 
Surgery. 2011;150(1):39-47. 
2. Heyman SN, Rosenberger C, Rosen S. Acute kidney in-
jury: lessons from experimental models. Contrib Nephrol. 
2011;169:286-96. 
3. Khajehdehi P. Turmeric: Reemerging of  a neglected 
Asian traditional remedy. Journal of  Nephropathology. 
2012;1(1). 
4. Uz E, Uz B, Kaya A, Akdeniz D, BavbekRuzgaresen N, 
HilmiTurgut F, et al. Protective effect of  erdosteine on cy-
closporine induced chronic nephrotoxicity in rats. Nephro-
Urology Monthly. 2011;3(04):280-4.
5. Rosen S, Stillman IE. Acute tubular necrosis is a syn-
drome of  physiologic and pathologic dissociation. J Am Soc 
Nephrol. 2008;19(5):871-5. 
6. Tayebi Khosroshahi H. Short history about renal trans-
plantation program in Iran and the world: Special focus 
on world kidney day 2012. Journal of  Nephropathology. 
2012;1(1). 
7. Tolou-Ghamari Z. Nephro and neurotoxicity, mecha-
nisms of  rejection: A review on Tacrolimus and Cyclosporin 
in organ transplantation. J Nephropathology. 2012;1(1):23-30. 
8. Bernhardt WM, Eckardt KU. Physiological basis for the 
use of  erythropoietin in critically ill patients at risk for acute 
kidney injury. Curr Opin Crit Care. 2008;14(6):621-6. 
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe 
GC. Delayed administration of  darbepoetin or erythropoi-
etin protects against ischemic acute renal injury and failure. 
Kidney Int. 2006;69(10):1806-13. 
10. Johnson DW, Forman C, Vesey DA. Novel renoprotec-
tive actions of  erythropoietin: new uses for an old hormone. 
Nephrology (Carlton). 2006;11(4):306-12. 
11. Provatopoulou ST, Ziroyiannis PN. Clinical use of  
erythropoietin in chronic kidney disease: outcomes and fu-
ture prospects. Hippokratia. 2011;15(2):109-15. 
12. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, 
Diederich M. Erythropoietin, erythropoiesis and beyond. 
Biochem Pharmacol. 2011;82(10):1291-303. 
13. RezaTamadon M, Khatibinezhad A, Ghorbani R, Solei-
mani A, Malek F, Jalalzadeh M, et al. The impact of  human 
recombinant erythropoietin on renal function in patients 
with chronic kidney disease. Nephro-Urology Monthly. 
2011;3(02):114-6. 
14. De Beuf  A, D’Haese PC, Verhulst A. Epoetin delta as 
an antiﬁbrotic agent in the remnant kidney rat: a possible 
role for transforming growth factor beta and hepatocyte 
growth factor. Nephron Exp Nephrol. 2010;115(3):e46-59. 
15. Moore E, Bellomo R. Erythropoietin (EPO) in acute 
kidney injury. Ann Intensive Care. 2011;1(1):3. 
16. Hariprasad G, Kumar M, Rani K, Kaur P, Srinivasan A. 
Aminoglycoside induced nephrotoxicity: molecular model-
ing studies of  calreticulin-gentamicin complex. J Mol Mod-
el. 2012;18(6):2645-52. 
17. Ali BH, Al Za’abi M, Blunden G, Nemmar A. Experi-
mental gentamicin nephrotoxicity and agents that modify 
it: a mini-review of  recent research. Basic Clin Pharmacol 
Toxicol. 2011;109(4):225-32. 
18. Tavaﬁ M, Ahmadvand H, Toolabi P. Inhibitory effect of  
olive leaf  extract on gentamicin-induced nephrotoxicity in 
rats. Iran J Kidney Dis. 2012;6(1):25-32. 
19. Tavaﬁ M, Ahmadvand H. Effect of  rosmarinic acid on 
inhibition of  gentamicin induced nephrotoxicity in rats. Tis-
sue Cell. 2011;43(6):392-7. 
20. Kopple JD, Ding H, Letoha A, Ivanyi B, Qing DP, Dux 
L, et al. L-carnitine ameliorates gentamicin-induced renal in-
jury in rats. Nephrol Dial Transplant. 2002;17(12):2122-31. 
21. Juan SH, Chen CH, Hsu YH, Hou CC, Chen TH, Lin 
H, et al. Tetramethylpyrazine protects rat renal tubular cell 
apoptosis induced by gentamicin. Nephrol Dial Transplant. 
2007;22(3):732-9. 
22. Kadkhodaee M, Khastar H, Arab HA, Ghaznavi R, 
Zahmatkesh M, Mahdavi-Mazdeh M. Antioxidant vitamins 
preserve superoxide dismutase activities in gentamicin-in-
Raﬁeian-Kopaei M et al.
Journal of  Nephropathology, Vol 1, No 2,  July 2012       www.nephropathol.com116
duced nephrotoxicity. Transplant Proc. 2007;39(4):864-5. 
23. Ghaznavi R, Kadkhodaee M. Comparative effects of  
selective and non-selective nitric oxide synthase inhibition 
in gentamicin-induced rat nephrotoxicity. Arch Toxicol. 
2007;81(6):453-7. 
24. Kadkhodaee M, Khastar H, Faghihi M, Ghaznavi R, 
Zahmatkesh M. Effects of  co-supplementation of  vitamins 
E and C on gentamicin-induced nephrotoxicity in rat. Exp 
Physiol. 2005;90(4):571-6. 
25. Derakhshanfar A, Bidadkosh A, Sadeghian M. L-methi-
onine attenuates gentamicin nephrotoxicity in male Wistar 
rat: pathological and biochemical ﬁndings. Iranian Journal 
of  Veterinary Research. 2009;10(4). 
26. Lee DW, Kwak IS, Lee SB, Song SH, Seong EY, Yang 
BY, et al. Post-treatment effects of  erythropoietin and nor-
dihydroguaiaretic acid on recovery from cisplatin-induced 
acute renal failure in the rat. J Korean Med Sci. 2009;24 
Suppl:S170-5. 
27. Jabbari M, Rostami Z, Jenabi A, Bahrami A, Mooraki A. 
Simvastatin ameliorates gentamicin-induced renal injury in 
rats. Saudi J Kidney Dis Transpl. 2011;22(6):1181-6. 
28. Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, 
Kheiri S, Baradaran A, et al. Oxford-MEST classiﬁcation 
in IgA nephropathy patients: A report from Iran. Journal of  
Nephropathology. 2012;1(1):31-42. 
29. Nematbakhsh M, Ashraﬁ F, Safari T, Talebi A, Nasri 
H, Mortazavi M, et al. Administration of  vitamin E and 
losartan as prophylaxes in cisplatin-induced nephrotoxicity 
model in rats. J Nephrol. 2012;25(3):410-7. 
30. ESHRAGHI JF, NEMATBAKHSH M, NASRI HA-
MID TA, HAGHIGHI M, PEZESHKI Z, SAFARI TA-
HEREH AF. The protective role of  endogenous nitric 
oxide donor (L-arginine) in cisplatin-induced nephrotox-
icity: Gender related differences in rat model. JOURNAL 
OF RESEARCH IN MEDICAL SCIENCES (JRMS). 
2011;16(11):1389-96. 
31. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson 
DW. Erythropoietin protects against ischaemic acute renal 
injury. Nephrol Dial Transplant. 2004;19(2):348-55. 
32. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances 
recovery from cisplatin-induced acute renal failure. Am J 
Physiol. 1994;266(3 Pt 2):F360-6. 
33. Bagnis C, Beauﬁls H, Jacquiaud C, Adabra Y, Jouanneau 
C, Le Nahour G, et al. Erythropoietin enhances recovery 
after cisplatin-induced acute renal failure in the rat. Nephrol 
Dial Transplant. 2001;16(5):932-8. 
34. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, et al. 
Preconditioning with erythropoietin protects against subse-
quent ischemia-reperfusion injury in rat kidney. FASEB J. 
2003;17(12):1754-5. 
35. Gong H, Wang W, Kwon TH, Jonassen T, Li C, Ring T, 
et al. EPO and alpha-MSH prevent ischemia/reperfusion-
induced down-regulation of  AQPs and sodium transporters 
in rat kidney. Kidney Int. 2004;66(2):683-95. 
36. Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin pre-
vents reactive oxygen species generation and renal tubular 
cell apoptosis at high glucose level. Biomed Pharmacother. 
2010;64(10):681-5. 
37. Chatterjee PK. Novel pharmacological approaches to 
the treatment of  renal ischemia-reperfusion injury: a com-
prehensive review. Naunyn Schmiedebergs Arch Pharma-
col. 2007;376(1-2):1-43. 
38. Ates E, Yalcin AU, Yilmaz S, Koken T, Tokyol C. Pro-
tective effect of  erythropoietin on renal ischemia and reper-
fusion injury. ANZ J Surg. 2005;75(12):1100-5. 
39. Rjiba-Touati K, Boussema IA, Belarbia A, Achour A, 
Bacha H. Protective effect of  recombinant human erythro-
poietin against cisplatin-induced oxidative stress and neph-
rotoxicity in rat kidney. Int J Toxicol. 2011;30(5):510-7. 
40. Rjiba-Touati K, Ayed-Boussema I, Bouaziz C, Belarbia 
A, Azzabi A, Achour A, et al. Protective effect of  eryth-
ropoietin against cisplatin-induced nephrotoxicity in rats: 
antigenotoxic and antiapoptotic effect. Drug Chem Toxicol. 
2012;35(1):89-95. 
41. Wang W, Zhang J. Protective effect of  erythropoietin 
against aristolochic acid-induced apoptosis in renal tubular 
epithelial cells. Eur J Pharmacol. 2008;588(2-3):135-40. 
42. Goldfarb M, Rosenberger C, Ahuva S, Rosen S, Hey-
man SN. A role for erythropoietin in the attenuation of  
radiocontrast-induced acute renal failure in rats. Ren Fail. 
2006;28(4):345-50. 
43. Ghaznavi R, Faghihi M, Kadkhodaee M, Shams S, Kha-
star H. Effects of  nitric oxide on gentamicin toxicity in iso-
lated perfused rat kidneys. J Nephrol. 2005;18(5):548-52. 
44. Nagai J, Takano M. Molecular aspects of  renal handling 
of  aminoglycosides and strategies for preventing the neph-
rotoxicity. Drug Metab Pharmacokinet. 2004;19(3):159-70. 
45. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, et 
al. Prevention of  acute kidney injury by erythropoietin in 
patients undergoing coronary artery bypass grafting: a pilot 
study. Am J Nephrol. 2009;30(3):253-60. 
46. Endre ZH, Walker RJ, Pickering JW, Shaw GM, 
Frampton CM, Henderson SJ, et al. Early interven-
tion with erythropoietin does not affect the outcome of  
acute kidney injury (the EARLYARF trial). Kidney Int. 
2010;77(11):1020-30. 
